Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

49.65 +0.78 (+1.60%)

Streaming Delayed Price Updated: 9:51 AM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

35 36 Next >

Why CRISPR Therapeutics Stock Is Moving Higher Monday ↗

November 06, 2023

CRISPR Therapeutics AG (NYSE: CRSP) shares are trading higher Monday after the company announced preclinical data for its investigational programs for the

Via Benzinga

2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now ↗

November 05, 2023

These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.

Via The Motley Fool

Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review ↗

November 03, 2023

Bulls are back in control as the major indexes confirmed the uptrend this week.

Via Investor's Business Daily

Why CRISPR Therapeutics Stock Charged Northward This Week ↗

November 03, 2023

Gene correction technology took a big step forward this week.

Via The Motley Fool

CRISPR Therapeutics Stock: Bull vs. Bear ↗

October 21, 2023

Here's the scoop on one of the most widely followed gene-editing stocks on the market.

Via The Motley Fool

Here's What Investors Need to Know About Vertex Pharmaceuticals and CRISPR Therapeutics' Big Day at the FDA ↗

November 03, 2023

The meeting went almost as well as could be expected.

Via The Motley Fool

3 Healthcare Stocks to Buy Hand Over Fist in November ↗

November 03, 2023

Get these stocks while they're cheap.

Via The Motley Fool

One Month Ahead of its Most Crucial Moment Ever, Should You Buy CRISPR Therapeutics? ↗

November 02, 2023

This stock could be a long-term winner, thanks to its game-changing technology.

Via The Motley Fool

Why Are Stocks Up Today? ↗

November 01, 2023

Stocks are up today as investors prepare for the most recent information from the Federal Reserve concerning interest rates.

Via InvestorPlace

Topics Economy

Why Is Aldeyra Therapeutics (ALDX) Stock Up 40% Today? ↗

November 01, 2023

Aldeyra Therapeutics stock is rising with heavy trading of ALDX shares after signing an exclusive option agreement with AbbVie.

Via InvestorPlace

Crispr Therapeutics Rallies On Bullish Views Of First-Ever Gene-Editing Drug ↗

November 01, 2023

The agency could soon approve a potential cure for sickle cell disease .

Via Investor's Business Daily

CRSP Stock Alert: Can CRISPR Therapeutics Short Squeeze Higher? ↗

November 01, 2023

CRSP stock is rallying after an FDA panel appeared to view CRISPR Therapeutics' sickle-cell anemia treatment as safe.

Via InvestorPlace

AMD, CRISPR Therapeutics, Paycom Software, DraftKings, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

October 31, 2023

Major U.S. indices ended in the green on Tuesday, with the Dow gaining nearly 124 points or 0.4% to 33,052.87.

Via Benzinga

Topics Stocks

CRSP Stock Halt: CRISPR Trading Halted Ahead of FDA Decision ↗

October 31, 2023

Investors in CRISPR and CRSP stock have certainly been on a wild ride so far this year. Here's what investors need to watch right now.

Via InvestorPlace

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗

October 30, 2023

This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term.

Via The Motley Fool

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy ↗

October 27, 2023

Although CRISPR Therapeutics may have a breakthrough drug on its hands, regulatory concerns hang over CRSP stock.

Via InvestorPlace

Questions Surround Vertex/CRISPR's Sickle Cell Gene Therapy As FDA AdComm Meeting Approaches ↗

October 27, 2023

The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee will meet next

Via Benzinga

Vertex Pharmaceuticals: Buy at the High? ↗

October 26, 2023

Vertex shares have been flying high in recent times.

Via The Motley Fool

2 Fantastic Growth Stocks to Buy Hand Over Fist ↗

October 26, 2023

These stocks make great bargains today.

Via The Motley Fool

2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗

October 25, 2023

Neither has performed well on the stock market this year.

Via The Motley Fool

3 No-Brainer Stocks to Buy Right Now for Less than $100 ↗

October 23, 2023

You can start with a small investment and win big over time.

Via The Motley Fool

7 Biotech Stocks to Get In Now Before Investors Catch On ↗

October 23, 2023

Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.

Via InvestorPlace

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time ↗

October 21, 2023

Wood is going all in on gene editing.

Via The Motley Fool

3 Gene Editing Stocks to Generate Super-Charged Gains ↗

October 18, 2023

As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.

Via InvestorPlace

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

Cathie Wood-Led Ark Invest Sells Over $6.5M Worth Of Tesla Stock, What's Going On? ↗

October 17, 2023

Via Benzinga

Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges ↗

October 17, 2023

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches...

Via Benzinga

Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗

October 17, 2023

Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw

Via Benzinga

Mixed Signals For CRISPR Therapeutics, Analyst Weighs Barriers, Potential Sales For Sickle Cell Therapy ↗

October 17, 2023

Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (NASDAQ: CRSP) to Neutral from Ov

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗

October 17, 2023

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.